Signal transducers and activators of transcription (STATs) mediate cell proliferation, differentiation, and survival in immune responses, hematopoiesis, neurogenesis, and other biological processes. STAT3, for example, is involved in the epithelialmesenchymal transition during gastrulation, organogenesis, wound healing, and cancer progression. STAT activity is regulated by a variety of mechanisms, including nuclear translocation. To clarify the molecular mechanisms underlying the regulation of STAT activity, we performed yeast two-hybrid screening. Here we identified BART (Binder of ADP-ribosylation factor-like Two) as a novel STAT-binding partner. Importantly, we showed that BART is essential for the transcriptional activity and nuclear retention of STAT3. Furthermore, an effector of BART, ADP-ribosylation factor-like 2 (ARL2) was also involved in nuclear retention of STAT3. These results indicate that BART plays an essential role in the nuclear retention of STAT3 through interaction with ARL2.
Introduction
The Jak/STAT pathways are utilized by a wide range of cytokines to regulate gene expression. Cytokines activate members of the Jak family of protein tyrosine kinases, which in turn activate, by tyrosine phosphorylation, one or more members of the STAT family of transcription factors. STATs are unusual among transcription factors in that they have the characteristics of cytoplasmic signaling molecules, such as a Srchomology 2(SH2) domain and tyrosine phosphorylation sites.
Upon tyrosine phosphorylation, the STATs dimerize through their phosphorylated SH2 domains and translocate to the nucleus (1, 2, 3) . In recent years, constitutive or dysregulated expression of STATs has been found in cancer cells and oncogene-transfected cells and shown to be involved in a wide range of diseases including autoimmune diseases (4-7).
Studies in Dictyostelium, Drosophila, and zebrafish have shown that the Jak/STAT pathway is required for a broad set of developmental processes, including cell proliferation, cell fate determination, cell migration, planar polarity, convergent extension, and immunity (8, 9) . These findings imply that STAT activation must be tightly regulated. In fact, STAT activation is regulated by a variety of mechanisms.
Cytoplasmic tyrosine phosphatases, such as SH2-containing phosphatase 1(SHP1), SHP2, and protein-tyrosine phosphatase 1B (PTP1B) prevent further STAT activation in the cytoplasm (10, 11) . The importin family proteins are involved in the nuclear translocation of STAT1 (12, 13) . Nuclear tyrosine phosphatases like TC45 dephosphorylate nuclear STATs, which allows the STATs to return to the cytoplasm (10).
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The PIAS family of proteins decreases STAT-dependent transcription by blocking STAT-DNA binding in the nucleus (10) . Suppressor of cytokine signaling (SOCS) is induced by STATs and plays roles in the negative feedback of STAT activation (11) .
Among these mechanisms, it is especially unclear how the nuclear localization of STATs is regulated.
To investigate the specific regulatory mechanisms of STATs, we sought to identify STAT-interacting proteins using yeast two-hybrid screening with the C-terminal region of STAT4 as bait. We identified, binder of ARL Two, BART, as a novel binding partner of STATs. BART is a 19-kDa protein originally identified as an ARL2-binding protein and purified from bovine brain, whose expression is ubiquitous (14) . ARL2
binds BART with high affinity and its binding is dependent on the binding of GTP to ARL2. BART lacks ARL2 GTPase-activating protein activity and, therefore, was the first effector identified for ARL2, although the function of their interaction remains unclear. Here, we show that BART is a STAT binding partner with a critical role in the nuclear retention of STAT3.
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Methods
Reagents and antibodies
Recombinant human IL-6 was a kind gift from Ajinomoto Co. (Tokyo, Japan).
Recombinant human LIF was purchased from INTERGEN (Purchase, NY (15) . Epipote-tagged STAT3 and its mutants were previously described (15, 16) .
Epitope-tagged BART or ARL2 and its mutants were generated by PCR and sequenced (primer sequences are available upon request). Anti-Myc, anti-GST, and anti-STAT3
antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-FLAG M2 monoclonal and rabbit polyclonal anti-FLAG were from Sigma (St Louis, MO). Antiphospho-STAT3 Tyr705 (pSTAT3 Tyr705) was purchased from Cell Signaling Technologies (Beverly, MA). Anti-BART monoclonal antibody was purchased from BD biosciences (San Jose, CA). Anti-ARL2 antibody was purchased from Abgent (San Diego, CA). Guinea pig anti-BART antibody was raised against GST-fused human BART.
Yeast two-hybrid screen
Gal4-STAT4 was constructed by fusing the coding sequence for the C-terminal region (amino acids 483-748) of mouse STAT4 in-frame to the Gal4 DNA-binding domain in the pGBKT7 vector (Clontech, Palo Alto, CA). S. cerevisiae AH109 cells were transformed with pGal4-STAT4, then mated with Y187 cells containing a pretransformed mouse 11-day embryo MATCHMAKER cDNA library (Clontech, Palo
Alto, CA) and approximately 2.6 x 106 colonies were screened as previously described (17) . Plasmid DNAs derived from positive clones were extracted from the yeast and sequenced.
Cell culture, transfection, luciferase assays, siRNA, RT-PCR and EMSA
The human hepatoma cell line Hep3B was cultured in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% fetal bovine serum (FBS). Hep3B cells were treated with an siRNA-Lipofectamine 2000 (Invitrogen, Carlsbad, CA) mixture at 37 °C for 4 h, followed by addition of fresh medium containing 10% FCS as previously described (18) . Further transfection into Hep3B transformant cells were performed using JetPEI (Polyplus, Illkirch, France) according to the manufacturer's instructions. (antisense). Human embryonic kidney carcinoma cell line, 293T, was maintained in DMEM containing 10% FBS, and treated with siRNAs as described the above. Cell extracts for EMSA were prepared from 293T cells left untreated or treated with LIF (100 ng /ml) for 30 min as previously described (19) . To measure STAT3 DNA binding, cell extracts were treated with 5'-biotin-labeled STAT3 consensus oligonucleotide and streptavidin-Sepharose beads (Sigma) conjugate in binding buffer (20 mM HEPES, 0.5 mM EDTA, 1 mM dithiothreitol, 2 mg/ml poly (dI-dC) ) and rotated for 2 h at 4°C. Samples were centrifuged, and the pellets were washed three times with binding buffer. Specifically bound proteins were eluted and subjected to
Western blot analysis using anti-STAT3 antibody.
Immunoprecipitation, immunoblotting and indirect immunofluorescence
Immunoprecipitation and Western blotting were performed as previously described (16) . 
Live cell imaging
293T cells were treated with siRNAs as described the above, and transfected with YFP-STAT3 using the calcium phosphate method. Twenty-four hours after transfection, cells were placed into a perfusion chamber. Stimulation was performed at 37°C with 100 ng/ml of LIF. Five minutes after stimulation a single cell was scanned every 20 sec for 240 min by confocal laser-scanning microscopy. Confocal microscopy was performed using an LSM510 system in conjunction with an Axiovert200 (Carl Zeiss MicroImaging, Inc.).
Results
Molecular interactions between STAT3 and BART
We performed a yeast two-hybrid screen of a mouse embryo cDNA library using the C-terminal region of STAT4 (amino acids 483-748) as bait. From a screen of about 2.6
x 10 6 transformants, we identified several positive clones. Sequence analysis revealed that one of them encoded the entire BART protein (amino acids 1-163). We examined the distribution of BART mRNA in murine tissues using RT-PCR and found that it was ubiquitously expressed, although it was abundant in the brain, heart, lung, bone marrow, and thymus, and was expressed at lower levels in the liver, kidney and spleen (data not shown). This distribution pattern was similar to that of human BART (14) , except that human BART expression is lower in the lung. enhances its binding to BART (Fig. 1E, F) . Moreover, an inactive form of STAT3, STAT3 YF mutant showed much less binding to BART than wild-type STAT3 or an active form of STAT3, STAT3-C (Fig. 1G) . To exclude the possibility that the interaction between STAT3 and BART was due to overexpression, we examined the direct binding between endogenous BART and STAT3 in untransfected 293T cells by co-immunoprecipitation. An anti-BART antibody co-immunoprecipitated STAT3 without LIF stimulation (Fig. 1H) , indicating that the binding of BART to STAT3 occurs at physiological expression levels without stimulation. However, their endogenous interaction was weak, suggesting that other molecules may be required for their stronger and a ligand-dependent interactions.
BART is required for STAT3-mediated transactivation
To clarify the molecular mechanisms underlying how BART affects STAT3 activity, we used small interfering RNA (siRNA) to reduce the endogenous expression of BART in Hep3B cells. We first examined whether reduction of endogenous BART expression affects STAT3-mediated gene expression using a BART-specific siRNA.
As shown in Fig. 2A , IL-6/STAT3-mediated SOCS3 mRNA expression was markedly reduced in BART siRNA-treated Hep3B cells. The LIF-induced STAT3-mediated transcriptional response of the a2-macroglobulin promoter was also suppressed in the human cervix carcinoma cell line, HeLa cells treated with BART siRNA (Fig. 2B ).
These results indicate that BART plays a role in the regulation of STAT3 activity in vivo.
Next, we examined whether reduction of BART expression affects phosphorylation of These results also demonstrated that nuclear localization of STAT3 protects phosphorylated STAT3 from dephosphorylation by PTPases.
BART is essential for the nuclear retention of STAT3
To further identify the molecular mechanisms underlying the effect of BART on the nuclear localization of STAT3, we perfomed time-lapse live cell imaging using yellow fluorescent protein (YFP)-fused STAT3 (YFP-STAT3). We transiently transfected YFP-STAT3 into 293T cells and observed nuclear translocation of YFP-STAT3 after LIF stimulation (Fig. 3A) . 
ARL2 T30N but not Q70L inhibits nuclear accumulation of STAT3
BART was first identified as the effector for an ARL family GTPase, ARL2 (14) .
ARF-like proteins (ARLs) are a functionally distinct group of incompletely characterized members of the ARF family of Ras-related GTPases (22) . The sequence analysis of BART did not reveal previously identified domains that might have provided insight into its function or other binding partners. Furthermore, the lack of a conserved GTPase or other, more general, protein-binding motifs is quite common among ARF family effectors.
BART binds specifically to ARL2ûGTP and with high affinity, and it does not interact with ARL2ûGDP or activated ARF or Rho proteins (14) . To first examine whether ARL2 is involved in interaction between STAT3 and BART, we estimated the binding potential of BART to STAT3 in the presence or absence of ARL2. Expression of ARL2 significantly enhanced interactions between STAT3 and BART (Fig. 4A) . Thus, ARL2 effectively bridges BART and STAT3. To examine whether activated ARL2 played a role in nuclear retention of STAT3, we generated ARL2 mutants Q70L and T30N (the numbers refer to the amino acids in ARL2), corresponding to the classical Ras mutations Q61L and T17N, and examined their binding to BART. Ras Q61L-or T17N-type mutations have the same 15 effect on many small G proteins: Q61L-type mutations are GTPase-defective (GTP remains bound), whereas T17N are defective in GTP binding and, when expressed in vivo, act in a dominant-negative manner, sequestering guanine nucleotide exchange factors, so that both mutant and endogenous proteins remain primarily GDP-bound. As shown in Fig   4B , a weak interaction between BART and ARL2 T30N was observed, whereas BART interacted strongly with wild-type ARL2 and ARL2 Q70L in 293T cells. We then examined whether overexpression of ARL2 T30N had any effect on the nuclear accumulation of STAT3 in Hep3B cells. Interestingly, when ARL2 T30N but not wildtype ARL2 was expressed together with STAT3, STAT3 did not accumulate in the nucleus even after IL-6 treatment (Fig. 4C, D) . Moreover, transfection of siRNA for ARL2 in HeLa cells suppressed LIF-induced nuclear accumulation of STAT3 (Fig. 4E) . These results suggest that the BART-ARL2ûGTP system plays an important role in the nuclear translocation of STAT3.
Discussion
Our findings led us to conclude that BART is indispensable for STAT3's nuclear retention. Reduction of endogenous BART inhibited STAT3-mediated transactivation.
We also provide the first evidence that BART is a nuclear retention factor for STAT3 using time-lapse live cell imaging. We further demonstrate the involvement of an ARL family GTPase, ARL2, in nuclear accumulation of STAT3. The interaction between STAT3 and a classical small GTPase, Rac1, has been reported previously (23); however, the biological significance of this interaction in relation to STAT3 function was not studied.
Protein localization is a highly dynamic biological process. To ensure a proper cellular function, the spatial distribution of different proteins needs to be tightly regulated and coordinated. Therefore, upon extracellular stimuli, STATs in the cytoplasm move to the nucleus as transcription factors, they need access to the nucleus.
Although the STAT proteins show structural similarity features, their nuclear-cytoplasmic localization has been shown to be differently regulated. After the importin-STAT1 complex enters the nucleus, the importin is released from the complex and STAT1 can then bind to DNA. Mutagenic studies showed that the DNAbinding domain of STAT1 is also required for its nuclear translocation (12, 13) .
Recently, in contrast to STAT1, STAT3 has been shown to accumulate in the nucleus independent of its phosphorylation state (24). Moreover, a reduction of importin-a3 expression by siRNA inhibits the nuclear localization of STAT3. Therefore, STAT3
continuously shuttles between nuclear and cytoplasmic compartments and can thereby respond to extracellular stimuli. The nuclear retention of unphosphorylated STAT3 might assist a rapid response of activated STAT3 by extracellular or intracellular stimuli.
This might be one reason that STAT3 is a pleiotropic transcription factor that is activated by several growth factors, hormones and intracellular tyrosine kinases.
Here we propose a novel scenario in which a STAT3-BART-ARL2 complex serves as machinery for STAT3 nuclear retention. Discovering every step of STAT3-specific nuclear translocation is important, since STAT3 may be a key player in the pathogenesis of diverse human diseases and a prime target for novel therapies. Specific inhibitors for the STAT3-BART-ARL2 pathway would be good candidates for STAT3-related human disease therapies. 
